Literature DB >> 28396914

[Anticoagulation in patients with chronic kidney disease : Recommendations from the working group "Heart-Kidney" of the German Cardiac Society and the German Society of Nephrology].

G Schlieper1,2, V Schwenger3, A Remppis4, T Keller5, R Dechend6, S Massberg7, S Baldus8, T Weinreich9, G Hetzel10, J Floege11, F Mahfoud12,13, D Fliser14.   

Abstract

Indications for anticoagulation are thromboembolic events, prosthetic heart valves, and atrial fibrillation with a corresponding risk score. Clinical trials have excluded patients with advanced chronic kidney disease and these data cannot be always generalized to patients with chronic kidney disease. Non-vitamin K antagonist oral anticoagulants (NOACs) are mostly not recommended or are contraindicated in advanced stages of chronic kidney disease. Observational studies have shown that dialysis patients with atrial fibrillation do not profit from coumarin anticoagulants; prospective studies are lacking.

Entities:  

Keywords:  Anticoagulants; Atrial fibrillation; Phenprocoumon; Renal disease; Warfarin

Mesh：

Substances：

Year:  2017        PMID： 28396914     DOI： 10.1007/s00108-017-0220-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  70 in total

1.  The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.

Authors:  Ziad Hijazi; Jonas Oldgren; Johan Lindbäck; John H Alexander; Stuart J Connolly; John W Eikelboom; Michael D Ezekowitz; Claes Held; Elaine M Hylek; Renato D Lopes; Agneta Siegbahn; Salim Yusuf; Christopher B Granger; Lars Wallentin
Journal:  Lancet       Date:  2016-04-04       Impact factor: 79.321

2.  Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis.

Authors:  Mitesh Shah; Meytal Avgil Tsadok; Cynthia A Jackevicius; Vidal Essebag; Mark J Eisenberg; Elham Rahme; Karin H Humphries; Jack V Tu; Hassan Behlouli; Helen Guo; Louise Pilote
Journal:  Circulation       Date:  2014-01-22       Impact factor: 29.690

Review 3.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

Review 4.  The vulnerable patient with chronic kidney disease.

Authors:  Georg Schlieper; Katharina Hess; Jürgen Floege; Nikolaus Marx
Journal:  Nephrol Dial Transplant       Date:  2015-03-04       Impact factor: 5.992

5.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

Authors:  Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

6.  Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.

Authors:  Jonas Bjerring Olesen; Gregory Y H Lip; Jesper Lindhardsen; Deirdre A Lane; Ole Ahlehoff; Morten Lock Hansen; Jakob Raunsø; Janne Schurmann Tolstrup; Peter Riis Hansen; Gunnar Hilmar Gislason; Christian Torp-Pedersen
Journal:  Thromb Haemost       Date:  2011-07-20       Impact factor: 5.249

7.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

8.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.

Authors:  David R Holmes; Saibal Kar; Matthew J Price; Brian Whisenant; Horst Sievert; Shephal K Doshi; Kenneth Huber; Vivek Y Reddy
Journal:  J Am Coll Cardiol       Date:  2014-07-08       Impact factor: 24.094

9.  Deep vein thrombosis in patients with chronic kidney disease.

Authors:  H Leon Daneschvar; Ali Seddighzadeh; Gregory Piazza; Samuel Z Goldhaber
Journal:  Thromb Haemost       Date:  2008-06       Impact factor: 5.249

10.  Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis.

Authors:  Pak-Hei Chan; Duo Huang; Pok-Siu Yip; Jojo Hai; Hung-Fat Tse; Tak-Mao Chan; Gregory Y H Lip; Wai-Kei Lo; Chung-Wah Siu
Journal:  Europace       Date:  2015-10-25       Impact factor: 5.214
View more
  3 in total

1.  Biased Results Owing to Competing Interests?

Authors:  Gisela Schott; Niklas Schurig
Journal:  Dtsch Arztebl Int       Date:  2018-09-14       Impact factor: 5.594

Review 2.  Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation.

Authors:  Gunnar H Heine; Vincent Brandenburg; Stephan H Schirmer
Journal:  Dtsch Arztebl Int       Date:  2018-04-27       Impact factor: 5.594

3.  Treatment standards for direct oral anticoagulants in patients with acute ischemic stroke and non-valvular atrial fibrillation: A survey among German stroke units.

Authors:  Christian Fastner; Kristina Szabo; Melina Samartzi; Mathieu Kruska; Ibrahim Akin; Michael Platten; Stefan Baumann; Angelika Alonso
Journal:  PLoS One       Date:  2022-02-17       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.